IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v10y2012i6p365-379.html
   My bibliography  Save this article

Inclusion of Compliance and Persistence in Economic Models

Author

Listed:
  • Ananth Kadambi
  • Robert Leipold
  • Anuraag Kansal
  • Sonja Sorensen
  • Denis Getsios

Abstract

Economic models are developed to provide decision makers with information related to the real-world effectiveness of therapeutics, screening and diagnostic regimens. Although compliance with these regimens often has a significant impact on real-world clinical outcomes and costs, compliance and persistence have historically been addressed in a relatively superficial fashion in economic models. In this review, we present a discussion of the current state of economic modelling as it relates to the consideration of compliance and persistence. We discuss the challenges associated with the inclusion of compliance and persistence in economic models and provide an in-depth review of recent modelling literature that considers compliance or persistence, including a brief summary of previous reviews on this topic and a survey of published models from 2005 to 2012. We review the recent literature in detail, providing a therapeutic-area-specific discussion of the approaches and conclusions drawn from the inclusion of compliance or persistence in economic models. In virtually all publications, variation of model parameters related to compliance and persistence was shown to have a significant impact on predictions of economic outcomes. Growing recognition of the importance of compliance and persistence in the context of economic evaluations has led to an increasing number of economic models that consider these factors, as well as the use of more sophisticated modelling techniques such as individual simulations that provide an avenue for more rigorous consideration of compliance and persistence than is possible with more traditional methods. However, we note areas of continuing concern cited by previous reviews, including inconsistent definitions, documentation and tenuous assumptions required to estimate the effect of compliance and persistence. Finally, we discuss potential means to surmount these challenges via more focused efforts to collect compliance and persistence data. Copyright Springer International Publishing AG 2012

Suggested Citation

  • Ananth Kadambi & Robert Leipold & Anuraag Kansal & Sonja Sorensen & Denis Getsios, 2012. "Inclusion of Compliance and Persistence in Economic Models," Applied Health Economics and Health Policy, Springer, vol. 10(6), pages 365-379, November.
    • Handle: RePEc:spr:aphecp:v:10:y:2012:i:6:p:365-379
    DOI: 10.1007/BF03261872
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/BF03261872
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/BF03261872?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Hiligsmann, Mickaël & Rabenda, Véronique & Bruyère, Olivier & Reginster, Jean-Yves, 2010. "The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients," Health Policy, Elsevier, vol. 96(2), pages 170-177, July.
    2. François-Emery Cotté & Bruno Fautrel & Gérard De Pouvourville, 2009. "A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis," Medical Decision Making, , vol. 29(1), pages 125-139, January.
    3. Christina M. L. Kelton & Margaret K. Pasquale, 2009. "Evaluating the Claim of Enhanced Persistence: The Case of Osteoporosis and Implications for Payers," Medical Decision Making, , vol. 29(6), pages 690-706, November.
    4. Cleemput, Irina & Kesteloot, Katrien & DeGeest, Sabina, 2002. "A review of the literature on the economics of noncompliance. Room for methodological improvement," Health Policy, Elsevier, vol. 59(1), pages 65-94, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt, 2014. "Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 133-142, March.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Katherine Baicker & Sendhil Mullainathan & Joshua Schwartzstein, 2015. "Behavioral Hazard in Health Insurance," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 130(4), pages 1623-1667.
    2. Karine Lamiraud & Pierre‐Yves Geoffard, 2007. "Therapeutic non‐adherence: a rational behavior revealing patient preferences?," Health Economics, John Wiley & Sons, Ltd., vol. 16(11), pages 1185-1204, November.
    3. Ana Teixeira & Maribel Teixeira & Maria Teresa Herdeiro & Viviana Vasconcelos & Rita Correia & Maria Fernanda Bahia & Isabel F. Almeida & Diogo Guedes Vidal & Hélder Fernando Pedrosa e Sousa & Maria A, 2021. "Knowledge and Practices of Community Pharmacists in Topical Dermatological Treatments," IJERPH, MDPI, vol. 18(6), pages 1-13, March.
    4. Abualbishr Alshreef & Nicholas Latimer & Paul Tappenden & Ruth Wong & Dyfrig Hughes & James Fotheringham & Simon Dixon, 2019. "Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Method," Medical Decision Making, , vol. 39(8), pages 910-925, November.
    5. van Esch, Thamar E.M. & Brabers, Anne E.M. & van Dijk, Christel E. & Gusdorf, Lisette & Groenewegen, Peter P. & de Jong, Judith D., 2017. "Increased cost sharing and changes in noncompliance with specialty referrals in The Netherlands," Health Policy, Elsevier, vol. 121(2), pages 180-188.
    6. Hiligsmann, Mickaël & Rabenda, Véronique & Bruyère, Olivier & Reginster, Jean-Yves, 2010. "The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients," Health Policy, Elsevier, vol. 96(2), pages 170-177, July.
    7. Karine Lamiraud & Pierre-Yves Geoffard, 2007. "Therapeutic non-adherence: a rational behavior revealing patient preferences?," Health Economics, John Wiley & Sons, Ltd., vol. 16(11), pages 1185-1204.
    8. Theodore Darkow & Henry Henk & Simu Thomas & Weiwei Feng & Jean-Francois Baladi & George Goldberg & Alan Hatfield & Jorge Cortes, 2007. "Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs," PharmacoEconomics, Springer, vol. 25(6), pages 481-496, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:10:y:2012:i:6:p:365-379. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.